Expert Opinion on Investigational Drugs

Papers
(The TQCC of Expert Opinion on Investigational Drugs is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Safety, pharmacokinetics, and efficacy of HY-072808 ointment, a novel PDE4 inhibitor, in adolescent and adult patients with mild-to-moderate AD113
New investigational drugs to treat Sjogren's syndrome: lessons learnt from immunology84
Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy79
A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, safety, tolerability, and immunogenicity profiles of biosimilar candidate AVT03 (70 mg/mL74
The treatment of advanced melanoma: a review of systemic and local therapies in combination with immune checkpoint inhibitors in phase 1 and 2 clinical trials73
Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?69
A randomized, Phase I study of the safety, tolerability, and pharmacokinetics of BI 764198, a transient receptor potential channel 6 (TRPC6) inhibitor, in healthy Japanese men62
Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases61
SGLT2 inhibitors: an evidence-based update on cardiovascular implications58
Theranostic strategies in sarcoma: preliminary clinical evidence54
The role of extracellular vesicles in immune cell exhaustion and resistance to immunotherapy48
Management of inflammaging in kidney diseases: focusing on the current investigational drugs43
Experimental drugs in clinical trials for COPD: artificial intelligence via machine learning approach to predict the successful advance from early-stage development to approval39
Experimental drugs for erosive esophagitis: what is in the clinical development pipeline?38
Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies33
Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis31
Ataxia-telangiectasia clinical trial landscape and the obstacles to overcome31
Kallikrein inhibitors for angioedema: the progress of preclinical and early phase studies30
Monoclonal antibodies targeting interleukins for systemic lupus erythematosus: updates in early clinical drug development30
Novel precision therapies for cholangiocarcinoma: an overview of clinical trials29
Investigational new drug approval of DA-1241: what we know about GPR119 targeting for MASH therapy?28
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese su27
Investigational drugs for the treatment of dysmenorrhea26
The role of 5-HT modulation in opioid withdrawal and neonatal opioid withdrawal syndrome: mechanisms and potential serotonergic targets26
Potassium channel modulators and schizophrenia: an overview of investigational drugs24
Metformin: evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease23
CD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors22
Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials20
Endothelin receptor antagonists for diabetic kidney disease: back to the future?20
Emerging treatments for chronic urticaria20
Recent developments in adjunct therapies for type 1 diabetes19
Current options and investigational drugs for the treatment of eosinophilic esophagitis19
Investigational agents for polymyalgia rheumatica treatment: assessing the critical needs for future development19
Assessing the clinical potential of plozasiran, an APOC3 siRNA therapy for severe hypertriglyceridemia19
The emerging role of immune checkpoint inhibitors for the treatment of breast cancer18
Investigational drugs for immune thrombocytopenia18
IgA nephropathy: an overview of drug treatments in clinical trials17
Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer17
Duchenne muscular dystrophy: promising early-stage clinical trials to watch17
Novel biomarkers for cholangiocarcinoma: how can it enhance diagnosis, prognostication, and investigational drugs? Part-116
Treatment of anemia in myelofibrosis: focusing on novel therapeutic options16
Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics16
Frontotemporal dementia: from genetics to therapeutic approaches16
Investigational regenerative medicine for non-traumatic osteonecrosis of the femoral head: a survey of registered clinical trials16
Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials16
Biosimilarity of HS-20090 to Denosumab in healthy Chinese subjects: a randomized, double-blinded, pharmacokinetics/pharmacodynamics study16
Novel systemic treatment approaches for metastatic pancreatic cancer15
Clinical application and potential pluripotent effects of hepatocyte growth factor in spinal cord injury regeneration15
Current experimental and early investigational agents for cardiac fibrosis: where are we at?15
Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal15
Investigational new drugs for the treatment of leishmaniasis15
The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists15
What is the progress of experimental drug development for fibromyalgia?15
NF1 alterations in cancers: therapeutic implications in precision medicine15
Investigational drugs for glaucoma: novel mechanistic approaches of preclinical agents14
Preclinical therapeutics for sickle cell disease: modern developments and future considerations14
Experimental drug treatments for hepatocellular carcinoma: clinical trial failures 2015 to 202114
Targeting a key FAK-tor: the therapeutic potential of combining focal adhesion kinase (FAK) inhibitors and chemotherapy for chemoresistant non-small cell lung cancer14
Assessing the clinical progress of the bispecific nanobody sonelokimab13
Investigative agents for atrial fibrillation: agonists and stimulants, progress and expectations13
MASLD and MASH: how a change of nomenclature may impact our approach in treating liver disease13
Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjects13
Investigational drugs for the treatment of olfactory dysfunction12
Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 partici12
Foreword: hepatocellular carcinoma: emerging treatments, drug targets, and fundamental knowledge gaps12
Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV)12
Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC)12
First-in-human trial of SAR107375E, a novel small molecule anticoagulant with dual inhibition of factor Xa and factor IIa12
Navafenterol for chronic obstructive pulmonary disease therapy12
Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions12
Progress in the treatment of anal cancer: an overview of the latest investigational drugs12
Inflammatory myopathies: shedding light on promising agents and combination therapies in clinical trials11
Clinical development of tri-specific antibodies for immune-oncology11
JAK inhibitors in crohn’s disease: ready to go?11
Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents11
Antibiotics and non-traditional antimicrobial agents for Pseudomonas aeruginosa in clinical phases 1, 2, and 3 trials11
Investigational thrombolytic drugs for acute ischemic stroke11
JAK inhibitors for rheumatoid arthritis11
Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia11
Immunotherapeutic strategies for treating opioid use disorder and overdose11
Investigational agents for pancreatic neuroendocrine tumors: what clinical progress have we seen in the last 5 years?10
Zelenectide pevedotin (BT-8009): a bicyclic peptide toxin conjugate targeting nectin-4 for the treatment of bladder cancer10
Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis10
Prospects of focal adhesion kinase inhibitors as a cancer therapy in preclinical and early phase study10
Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosus10
Emerging agents for the treatment and prevention of stroke: progress in clinical trials10
Emerging neuroprotective interventions in periventricular leukomalacia - A systematic review of preclinical studies10
Investigational new drugs for the treatment of Dravet syndrome: an update10
Camrelizumab: an investigational agent for hepatocellular carcinoma10
Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension9
Investigational anti IL-13 asthma treatments: a 2023 update9
Preclinical prospects of investigational agents for hearing loss treatment9
Approaches to combating methicillin-resistant Staphylococcus aureus (MRSA) biofilm infections9
Inflammation and Huntington’s disease – a neglected therapeutic target?9
PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers9
Assessing potential of psilocybin for depressive disorders9
The bispecific antibody AZD0486: an overview of the clinical journey to date with a focus on follicular lymphoma9
Investigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials9
A four-in-one first-in-human study to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and concentration-QTc relationship of HRS-1780, a selective non-steroidal mineralocorticoid recep9
The impact of current investigational drugs for acne on future treatment strategies9
Prospects of current AXL-targeting therapies in early phase cancer trials9
Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress9
Heart failure with preserved ejection fraction: key stumbling blocks for experimental drugs in clinical trials9
New treatment approaches for Alzheimer’s disease: preclinical studies and clinical trials centered on antidiabetic drugs9
Pharmacological agents for bone fracture healing: talking points from recent clinical trials9
Potential of BGB-11417, a BCL2 inhibitor, in hematological malignancies9
0.09648609161377